Stock Groups

Stryker Earnings, Revenue Miss in Q3 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Stryker earnings, revenue miss in Q3

Investing.com Stryker (NYSE:) Thursday’s third quarter report showed revenue that was below analysts’ expectations and forecasts that were not met.

Stryker posted earnings per share (EPS) of $2.2 on $4.16 billion in revenue. Investing.com polled analysts and predicted EPS at $2.29 for revenue $4.23B.

Stryker shares fell 2% over the first of the year. Still, it is down 4.51% against its 52-week peak of $281.16 which was set September 9. They are under-performing the S&P 500 which is up 22.37% from the start of the year.

Stryker shares fell 3.16% after hours trades following the report.

Stryker is following other notable earnings from the Healthcare sector this month

Stryker’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.

Thermo Fisher Scientific beat all expectations Wednesday, posting a third quarter EPS (EPS) of $5.76 on revenues of $9.33B compared with a forecast of EPS (4.68 for revenue of $8.33B).

You can keep up-to date on the latest earnings reports by visiting Investing.com’s earnings calendar

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]